You’ve probably heard of the recent advances in Oral Immunotherapy (OIT) where patients are given very small amounts of peanut protein that do not trigger a reaction, and then increasing the dose over time to increase the amount the body can tolerate. A study by researchers from the University of Adelaide in Australia found that adding antihistamines and probiotics increase the success rate by 10%. Overall, the study found that the treatment worked in around 70% of children, so it might be worth asking your doctor for more information.
Co-treatments like antihistamines and probiotics make successful de-sensitisation treatment of peanut allergy in children via oral immunotherapy 10 percent more likely, researchers from the University of Adelaide have found.
Speaking of Oral Immunotherapy (OIT), one mother is asking if her son ever passed an oral food challenge, how would she know if this was a reliable result — and not just a good immune system day? An allergist replies that there are many variables that influence the reaction from ingesting an allergen, but he feels confident that it would be safe to add food to the diet if it was shown to be tolerated during an oral food challenge.
Q: My son is 16, with multiple food allergies since he was a toddler. Over the years, he’s had four experiences with anaphylaxis, but food errors have mostly been confined to mild reactions. As his reactions vary, my question is: If my son ever passed an oral food challenge, how would he know if this was a reliable result — and not just a good immune system day?
Dr. Sicherer: One reason reaction severity may vary has to do with the amount of the allergen consumed.
For example, a person may have mild or even no symptoms with eating one peanut, but have severe symptoms if 15 peanuts are eaten.
2020/02/06 -Pre-IND Meeting on AQST-108 Completed -FDA Confirmed AQST-108 To Be Reviewed Under 505(b)(2) -No Additional Clinical Studies Would Be Required Prior to Opening Proposed IND -Pivotal Pharmacokinetic (PK) Clinical Trials Planned To Be Initiated Before Year End 2020
WARREN, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) — Aquestive Therapeutics (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients’ unmet needs and solve therapeutic problems, announced today that it had a constructive face-to-face pre-Investigational New Drug (IND) Application meeting with the U.S. Food and Drug Administration (FDA) for its drug candidate, AQST-108, a “first of its kind” oral sublingual film formulation delivering systemic epinephrine that is in development for the treatment of anaphylaxis using Aquestive’s proprietary PharmFilm® technologies.